The Phenotyping and Genotyping of Taiwanese Patients With Obstructive Sleep Apnea
1 other identifier
observational
360
1 country
1
Brief Summary
The growing evidence showed that the OSA is a heritable complex genetic disease where the genetic basis contributed the development of OSA and its sequel. The phenotyping of OSA include high level and intermediate level. The former indicates the AHI, and later includes craniofacial morphology, ventilator control, obesity, and sleepiness vulnerability. Many studies tried to determine the association of candidate genes with OSA through association studies. However, the results were conflicting. We identified 37 candidate genes involved in six biologic pathways of OSA reported in previous literatures, including oxidative phosphorylation, cell signaling, apoptosis, cellular adhesion and motility, cell cycle, and cytokine/chemokine. To investigate the association between phenotype and genotype of OSA, we conducted this cross-sectional study by recruiting the patients of moderate-severe OSA (index proband) and their first and second-degree family members, and friends and their family members (control family) and using candidate genes reported in the literature and whole genome SNP array for genotype approach.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedFirst Submitted
Initial submission to the registry
January 15, 2014
CompletedFirst Posted
Study publicly available on registry
January 17, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedJanuary 17, 2014
January 1, 2014
2.9 years
January 15, 2014
January 16, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Family aggregation of OSA and its phenotype
Phenotypes assessment by PSG, craniofacial image, Hypercapnic ventilatory response testing, psychomotor vigilance task, MSLT, blood biochemistry testing, abdominal MRI, and 24 hr ambulatory BP monitor Family aggregation assessed by family-based study design (1. to compare risk of OSA between index and control proband; 2. to compare risk between index proband with more than one families suffering OSA and without; 3. to calculate inter-generation and intra-generation association index of AHI)
within the first half year after enrollment
Association between phenotype and genotype of OSA
Genotypes assessed by candidate genes identification or whole genome SNP array Phenotypes assessment by PSG, craniofacial image, Hypercapnic ventilatory response testing, psychomotor vigilance task, MSLT, blood biochemistry testing, abdominal MRI, and 24 hr ambulatory BP monitor Association assessed by linkage study and association study
within the first half year after enrollment
Study Arms (4)
Index proband
moderate to severe OSA (AHI\>30 or AHI\>15 needing CPAP intervention) age 20-99 y/o
Index family
first-degree, second-degree, or spouse of index proband age \>20 y/o
Control proband
friends of index proband, living in the same environment as index proband age \> 20 y/o
Control family
first-degree, second-degree, or spouse of control proband age \>20 y/o
Eligibility Criteria
moderate to severe OSA from primary care clinic friends and families from recommendation of OSA patients
You may qualify if:
- all participants needing age \> 20 y/o
- Index proband: OSA diagnosed by overnight polysomnography (AHI\>30 or AHI\>15 needing therapeutic intervention)
- Index family: first-degree, second-degree relatives, or spouse of index proband
- Control proband: friends recommended by index proband, who lived in the same environment as index proband
- Control family: first-degree, second-degree relatives, or spouse of control proband
You may not qualify if:
- Severe CHF, COPD, CKD
- Psychiatric disorder who can't coordinate to receive evaluation
- Autoimmune disorders
- Other sleep disorders
- Refusing to anticipate or involving other study at the same time
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Center of sleep disorders, National Taiwan University Hospital
Taipei, 100, Taiwan
Biospecimen
whole blood and serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peilin Lee, M.D, Ph.D.
Center of sleep disorders, National Taiwan University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 15, 2014
First Posted
January 17, 2014
Study Start
January 1, 2014
Primary Completion
December 1, 2016
Study Completion
December 1, 2016
Last Updated
January 17, 2014
Record last verified: 2014-01